Ambroxol
Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
N/A
Tablet: Gastrointestinal Disorders: Dyspepsia, nausea, vomiting, diarrhoea and abdominal pain. Immune System, Skin and Subcutaneous Tissue Disorders: Anaphylactic reactions including anaphylactic shock, angioedema, rash, urticaria, pruritus and other hypersensitivity. Syrup: Gastrointestinal, Respiratory, Mediastinal and Thoracic Disorders: Dyspepsia, nausea, vomiting, diarrhoea and abdominal pain; oral and pharyngeal hypoaesthesia; dry mouth and throat. Nervous System Disorders: Dysgeusia (eg, changed taste). Immune System, Skin and Subcutaneous Tissue Disorders: Anaphylactic reactions including anaphylactic shock, angioedema, rash, urticaria, pruritus and other hypersensitivity.
Ambroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency.
No clinically relevant unfavourable interaction with other medications has been reported.
N/A
Syrup: Adults -10 ml (2 teaspoonful), 3 times a day. SR Capsule : Adults - 1 capsule, once daily
Paediatric Drops : 0 - 6 months old - 0.5 ml, 2 times a day, 6 - 12 months old - 1 ml, 2 times a day, 1 - 2 years old -1.25 ml, 2 times a day. Syrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, 5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, 10 years old - 10 ml (2 teaspoonful), 3 times a day. SR Capsule : Children over 12 years old - 1 capsule, once daily
N/A
Can be taken with or without food.
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.